Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPItello-280: capivasertib plus docetaxel in metastatic castration-resistant prostate cancer
jRCT2031220214Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031220214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220214.